<DOC>
	<DOCNO>NCT02557100</DOCNO>
	<brief_summary>The purpose study examine change immune cell proteins response treatment two approve therapy Rheumatoid arthritis ( RA ) , abatacept versus adalimumab , give combination methotrexate .</brief_summary>
	<brief_title>Study Assess Changes Immune Profile Adults With Early Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Symptoms RA 12 month prior enrollment Meet American College Rheumatology/European League Rheumatism ( ACR/EULAR ) 2010 criterion classification RA Treated Methotrexate ( MTX ) least 12 week prior randomization stable oral dose least 4 week , Subjects must randomize maximum tolerate dose oral methotrexate ( minimum 15 mg maximum 25 mg per week ) , dose MTX &lt; 15 mg/week â‰¥ 7.5 mg/week permit subject intolerant high dos At least 3 tender &amp; 3 swollen joint Anticyclic citrullinated peptide ( CCP ) &gt; 3X upper limit normal positive rheumatoid factor History autoimmune disease ( eg , psoriasis , systemic lupus , erythematosus , etc ) Prior use nonbiologic therapy methotrexate Prior use biologic target synthetic diseasemodifying antirheumatic drug ( DMARD ) therapy Subjects chronic recent acute serious infection Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>